{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Condition&page=29", "query": { "condition": "Skin Condition", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 16278, "total_pages": 1628, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Condition&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Condition&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T20:05:30.072Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01105923", "title": "Study of an Intervention to Improve Problem List Accuracy and Use", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Attention Deficit Disorder With Hyperactivity", "Asthma", "COPD", "Breast Cancer", "Coronary Artery Disease", "Congestive Heart Failure", "Diabetes", "Glaucoma", "Hemophilia", "Hypertension", "Hyperthyroidism", "Hypothyroidism", "Myasthenia Gravis", "Osteoporosis", "Osteopenia", "Renal Failure", "Renal Insufficiency", "Sickle Cell Disease", "Stroke" ], "interventions": [ { "name": "MAPLE", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2010-05", "completion_date": "2017-11", "has_results": false, "last_update_posted_date": "2015-02-02", "last_synced_at": "2026-10-25T20:05:30.072Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01105923" }, { "nct_id": "NCT00746746", "title": "A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "HyperAcute vaccine", "type": "BIOLOGICAL" }, { "name": "Pegylated Interferon-Alpha 2b", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Ochsner Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 30, "start_date": "2008-06", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2011-01-13", "last_synced_at": "2026-10-25T20:05:30.072Z", "location_count": 1, "location_summary": "New Orleans, Louisiana", "locations": [ { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00746746" }, { "nct_id": "NCT03877146", "title": "Calming Alternatives Learned During MRI-Guided Breast Biopsy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Breast Pain", "Pain, Acute", "Anxiety", "Coping Skills", "Self Efficacy" ], "interventions": [ { "name": "Controlled Breathing Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 58, "start_date": "2018-10-16", "completion_date": "2019-06-20", "has_results": false, "last_update_posted_date": "2020-09-25", "last_synced_at": "2026-10-25T20:05:30.072Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03877146" }, { "nct_id": "NCT05962788", "title": "Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Adolescent Lupus Nephritis", "Pediatric Lupus Nephritis" ], "interventions": [ { "name": "voclosporin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aurinia Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "5 Years to 17 Years" }, "enrollment_count": 4, "start_date": "2024-03-28", "completion_date": "2025-07-04", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-10-25T20:05:30.072Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05962788" }, { "nct_id": "NCT01185288", "title": "A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Adalimumab", "type": "BIOLOGICAL" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 309, "start_date": "2010-09", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2014-03-18", "last_synced_at": "2026-10-25T20:05:30.072Z", "location_count": 46, "location_summary": "Huntsville, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 40 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01185288" }, { "nct_id": "NCT04007588", "title": "A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma Stage III", "Melanoma Stage IV" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "BMS-986205", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-09-06", "completion_date": "2019-12-19", "has_results": false, "last_update_posted_date": "2020-02-05", "last_synced_at": "2026-10-25T20:05:30.072Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04007588" }, { "nct_id": "NCT07532603", "title": "A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Lichen Planopilaris" ], "interventions": [ { "name": "Oral Brepocitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Priovant Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 342, "start_date": "2026-03-19", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-25T20:05:30.072Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07532603" }, { "nct_id": "NCT03524170", "title": "Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Breast Carcinoma", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Bintrafusp Alfa", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2018-04-30", "completion_date": "2022-02-10", "has_results": false, "last_update_posted_date": "2022-03-07", "last_synced_at": "2026-10-25T20:05:30.072Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03524170" }, { "nct_id": "NCT00005617", "title": "Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "dendritic cell-MART-1 peptide vaccine", "type": "BIOLOGICAL" }, { "name": "leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1997-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-10-25T20:05:30.072Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005617" }, { "nct_id": "NCT07665268", "title": "Study Title: A Multicenter, Prospective, Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Skin Ulcer", "Pressure Ulcer (PU)", "Pressure Ulcer of Skin", "Pressure Sore", "Chronic Ulcer", "Pressure Wound" ], "interventions": [ { "name": "Activate™ Matrix + SOC", "type": "OTHER" }, { "name": "AmnioDefend™ FT Matrix + SOC", "type": "OTHER" }, { "name": "Palisade™ DM Matrix + SOC", "type": "OTHER" }, { "name": "Sentry™ SL Matrix + SOC", "type": "OTHER" }, { "name": "Shelter™ DM Matrix + SOC", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Sequence LifeScience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2000, "start_date": "2026-01-28", "completion_date": "2028-01-28", "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-10-25T20:05:30.072Z", "location_count": 1, "location_summary": "North Royalton, Ohio", "locations": [ { "city": "North Royalton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07665268" } ] }